Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response.
Saved in:
| Title: | Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response. |
|---|---|
| Authors: | Zha, Yongchao1 (AUTHOR), Fu, Li1 (AUTHOR), Liu, Zonghua1 (AUTHOR) tliuzonghua@jnu.edu.cn, Lin, Jiansheng2 (AUTHOR) linjiansheng1020@163.com, Huang, Linghong1 (AUTHOR) tohlhong@163.com |
| Source: | Journal of Nanobiotechnology. 5/8/2024, Vol. 22 Issue 1, p1-17. 17p. |
| Subjects: | Cancer vaccines, Complementary DNA, Immune response, Base pairs, Combined vaccines, Ovalbumins, CD8 antigen |
| Abstract: | Tumor vaccines, a crucial immunotherapy, have gained growing interest because of their unique capability to initiate precise anti-tumor immune responses and establish enduring immune memory. Injected tumor vaccines passively diffuse to the adjacent draining lymph nodes, where the residing antigen-presenting cells capture and present tumor antigens to T cells. This process represents the initial phase of the immune response to the tumor vaccines and constitutes a pivotal determinant of their effectiveness. Nevertheless, the granularity paradox, arising from the different requirements between the passive targeting delivery of tumor vaccines to lymph nodes and the uptake by antigen-presenting cells, diminishes the efficacy of lymph node-targeting tumor vaccines. This study addressed this challenge by employing a vaccine formulation with a tunable, controlled particle size. Manganese dioxide (MnO2) nanoparticles were synthesized, loaded with ovalbumin (OVA), and modified with A50 or T20 DNA single strands to obtain MnO2/OVA/A50 and MnO2/OVA/T20, respectively. Administering the vaccines sequentially, upon reaching the lymph nodes, the two vaccines converge and simultaneously aggregate into MnO2/OVA/A50-T20 particles through base pairing. This process enhances both vaccine uptake and antigen delivery. In vitro and in vivo studies demonstrated that, the combined vaccine, comprising MnO2/OVA/A50 and MnO2/OVA/T20, exhibited robust immunization effects and remarkable anti-tumor efficacy in the melanoma animal models. The strategy of controlling tumor vaccine size and consequently improving tumor antigen presentation efficiency and vaccine efficacy via the DNA base-pairing principle, provides novel concepts for the development of efficient tumor vaccines. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Nanobiotechnology is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: egs DbLabel: Engineering Source An: 177112860 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Zha%2C+Yongchao%22">Zha, Yongchao</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fu%2C+Li%22">Fu, Li</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liu%2C+Zonghua%22">Liu, Zonghua</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> tliuzonghua@jnu.edu.cn</i><br /><searchLink fieldCode="AR" term="%22Lin%2C+Jiansheng%22">Lin, Jiansheng</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> linjiansheng1020@163.com</i><br /><searchLink fieldCode="AR" term="%22Huang%2C+Linghong%22">Huang, Linghong</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> tohlhong@163.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Journal+of+Nanobiotechnology%22">Journal of Nanobiotechnology</searchLink>. 5/8/2024, Vol. 22 Issue 1, p1-17. 17p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Cancer+vaccines%22">Cancer vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Complementary+DNA%22">Complementary DNA</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+response%22">Immune response</searchLink><br /><searchLink fieldCode="DE" term="%22Base+pairs%22">Base pairs</searchLink><br /><searchLink fieldCode="DE" term="%22Combined+vaccines%22">Combined vaccines</searchLink><br /><searchLink fieldCode="DE" term="%22Ovalbumins%22">Ovalbumins</searchLink><br /><searchLink fieldCode="DE" term="%22CD8+antigen%22">CD8 antigen</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Tumor vaccines, a crucial immunotherapy, have gained growing interest because of their unique capability to initiate precise anti-tumor immune responses and establish enduring immune memory. Injected tumor vaccines passively diffuse to the adjacent draining lymph nodes, where the residing antigen-presenting cells capture and present tumor antigens to T cells. This process represents the initial phase of the immune response to the tumor vaccines and constitutes a pivotal determinant of their effectiveness. Nevertheless, the granularity paradox, arising from the different requirements between the passive targeting delivery of tumor vaccines to lymph nodes and the uptake by antigen-presenting cells, diminishes the efficacy of lymph node-targeting tumor vaccines. This study addressed this challenge by employing a vaccine formulation with a tunable, controlled particle size. Manganese dioxide (MnO2) nanoparticles were synthesized, loaded with ovalbumin (OVA), and modified with A50 or T20 DNA single strands to obtain MnO2/OVA/A50 and MnO2/OVA/T20, respectively. Administering the vaccines sequentially, upon reaching the lymph nodes, the two vaccines converge and simultaneously aggregate into MnO2/OVA/A50-T20 particles through base pairing. This process enhances both vaccine uptake and antigen delivery. In vitro and in vivo studies demonstrated that, the combined vaccine, comprising MnO2/OVA/A50 and MnO2/OVA/T20, exhibited robust immunization effects and remarkable anti-tumor efficacy in the melanoma animal models. The strategy of controlling tumor vaccine size and consequently improving tumor antigen presentation efficiency and vaccine efficacy via the DNA base-pairing principle, provides novel concepts for the development of efficient tumor vaccines. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Journal of Nanobiotechnology is the property of BioMed Central and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=177112860 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1186/s12951-024-02498-1 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 17 StartPage: 1 Subjects: – SubjectFull: Cancer vaccines Type: general – SubjectFull: Complementary DNA Type: general – SubjectFull: Immune response Type: general – SubjectFull: Base pairs Type: general – SubjectFull: Combined vaccines Type: general – SubjectFull: Ovalbumins Type: general – SubjectFull: CD8 antigen Type: general Titles: – TitleFull: Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Zha, Yongchao – PersonEntity: Name: NameFull: Fu, Li – PersonEntity: Name: NameFull: Liu, Zonghua – PersonEntity: Name: NameFull: Lin, Jiansheng – PersonEntity: Name: NameFull: Huang, Linghong IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 05 Text: 5/8/2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 14773155 Numbering: – Type: volume Value: 22 – Type: issue Value: 1 Titles: – TitleFull: Journal of Nanobiotechnology Type: main |
| ResultId | 1 |
